April 22, 2026 -- OrganaBio, LLC ("OrganaBio"), a vertically integrated blood and cell products and services company delivering end-to-end solutions for cell and gene therapy developers, and RxMP Therapeutics, Inc. ("RxMP"), a late pre-clinical development stage therapeutics company developing novel therapies for the rapid control of severe hemorrhage, today announced a manufacturing partnership under which OrganaBio will serve as RxMP's contract manufacturing partner for the cGMP production of

Patient dosing commenced in Wave II, a multicenter Phase 2/3 study evaluating THRV-1268 in genetically confirmed Long QT Syndrome (LQTS) Type 2; enrollment at leading centers throughout the United States is advancing on track. FDA Fast Track Designation granted for THRV-1268 in LQTS Type 2 and Type 3, supporting expedited development of an investigational therapy targeting QTc reduction and arrhythmic risk in genetically defined LQTS populations. April 22, 2026 --- Thryv Therapeutics Inc., a cl

Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced the discontinuation of the Phase 3 STAR-121 study due to futility. STAR-121 study, which is being conducted in collaboration with Arcus Biosciences, Inc. (“Arcus”) and Gilead Sciences, Inc. (“Gilead”), evaluated the anti-TIGIT antibody domvanalimab (development code: AB154) plus anti-PD-1 antibody zimberelimab (development code: AB122) and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment for metastatic non-smal

– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed) – mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23% – No Grade 3 or higher adverse events related to RZ-001 observed – Highlights clinical potential of RNA trans-splicing ribozyme platform technology April 20, 2026 --- Rznomics announced today that it presented interim clinical data from its ongoing study of RZ-001, an RNA editing-based investigational anticancer therapy, in patients with hepatocellular carcinoma

Data demonstrate potent multi-target activity, high specificity, and a novel approach to overcoming fundamental limitations of T cell engagers in solid tumors April 20, 2026 -- Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today presented new preclinical data for its lead program, DBXO-1, at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held April 17–22 in San Diego, California. The data were included

AstraZeneca announced Tuesday that a Phase III study of Ultomiris (ravulizumab) in adults with IgA nephropathy (IgAN) met its primary endpoint, setting up marketing applications for the long-acting C5 complement inhibitor in this indication. "These positive data demonstrate that C5 complement inhibition with Ultomiris results in a rapid and clinically meaningful reduction in proteinuria as early as week 10 and underscores its potential as a disease-modifying approach in IgAN," said Marc Dunoyer

Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyyb) Findings emphasize clinical decision-making in long-term management of inflammatory bowel disease (IBD), reinforcing Celltrion's commitment to elevating the standard of care and addressing unmet medical need in gastroenterology April 21, 2026 -- Celltrion, Inc. today announced that seven abstrac

Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indication in cisplatin-ineligible muscle-invasive bladder cancer (MIBC), if approved, this regimen would be the first and only perioperative treatment for patients with MIBC regardless of cisplatin eligibility, marking a potential new standard of care April 20, 2026 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer

April 20, 2026 -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myeloma models, highlighting its potential to address key limitations of conventional CAR-T therapies. Autologous CAR-T therapy has achieved remarkable success in hematologic malignancies, yet its widespread use remains challenging

Novo Nordisk said Monday that its sickle cell disease pill succeeded in a late-stage study. However, the data came in behind expectations the company set last year. Etavopivat cut the occurrence of the painful sickle cell complications known as vaso-occlusive crises (VOCs) by 27% compared with placebo, hitting one of the trial’s co-primary endpoints. However, the company’s then-head of rare disease Ludovic Helfgott told Endpoints News last year that Novo was hoping to see a 50% cut. Nonetheles